Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 16/20 | 0.60 |
| ▸ | CPT2 | P23786 | 15/20 | 0.60 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743864 | 0.89 | ALDH1A1 (0.63) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL3148212 | 0.89 | ALDH1A1 (0.63) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL11481661 | 0.86 | CPT1A (0.60) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL7167933 | 0.86 | CPT1A (0.60) | CPT1ACPT2CPT1BMEN1KMT2A | |
| SCHEMBL11424895 | 0.85 | CPT1A (0.67) | CPT1ACPT2CPT1BALDH1A1SMN1; SMN2 | |
| SCHEMBL9094927 | 0.83 | CPT2 (0.62) | CPT1ACPT2CPT1B | |
| SCHEMBL9094912 | 0.83 | CPT2 (0.62) | CPT1ACPT2CPT1B | |
| SCHEMBL3187180 | 0.83 | ALDH1A1 (0.61) | CPT1ACPT2MEN1KMT2AALDH1A1 | |
| SCHEMBL3187156 | 0.83 | ALDH1A1 (0.61) | CPT1ACPT2MEN1KMT2AALDH1A1 | |
| SCHEMBL6794537 | 0.81 | ALDH1A1 (0.57) | CPT1ACPT2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | CPT1A 385/4885CPT2 2665/4885CPT1B 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.